About Catalyst Biosciences
Catalyst Biosciences is a company based in San Francisco (United States) founded in 1997. Catalyst Biosciences has raised $164.82 million across 14 funding rounds from investors including Pfizer, Novartis and Icon Ventures. The company has 26 employees.
- Headquarter San Francisco, United States
- Employees 26
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website catalystbiosciences.com
- Social LinkedIn Facebook
- Legal Name Crescent Biopharma, Inc.
- Annual Revenue$10.84 M (USD)0as on Dec 31, 2025
- Net Profit-$153.94 M (USD)-761.6as on Dec 31, 2025
- EBITDA-$152.55 M (USD)-787.37as on Dec 31, 2025
- Total Equity Funding$164.82M (USD)
in 14 rounds
- Latest Funding Round$1.89M (USD), Post-IPO
Jul 2015
- InvestorsPfizer
& 22 more
- Employee Count26
Funding Insights of Catalyst Biosciences
Catalyst Biosciences has successfully raised a total of $164.82M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.89 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $164.82M
- Total Rounds 14
- Last Round Post-IPO — $1.89M
- First Round $31.52M
(Aug 2000)
- Investors Count 23
Latest 10 of 14 funding rounds of Catalyst Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $1.89M | Post-IPO | – | – | – |
| Feb 2015 | $3.22M | Post-IPO | – | – | – |
| Apr 2014 | $5.01M | Post-IPO | – | – | – |
| Aug 2013 | $400,004 | Post-IPO | – | – | – |
| Apr 2013 | $5.07M | Post-IPO | – | – | |
| Sep 2012 | $13.41M | Post-IPO | – | – | – |
| Jan 2012 | $7M | Post-IPO | – | – | |
| Dec 2008 | $40.4M | Post-IPO | – | – | |
| Feb 2006 | $30M | Series B | – | Morgenthaler | |
| Dec 2004 | $33M | Series B | – | Phase4 Partners | – |
23 investors in total: 23 institutional.
Investors in Catalyst Biosciences
Catalyst Biosciences has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novartis and Icon Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | hcven.com | - | |
Venture capital firm backed by Johnson & Johnson | – | jnjinnovation.com/jjdc | Cambridge, United States | |
Venture capital and private equity investment firm | – | morgenthaler.com | Portola Valley, United States | |
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | – | ewhealthcare.com | New York, United States | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
Research Corporation Technologies is engaged in licensing biomedical technologies. | – | rctech.com | Tucson, United States | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Venture capital investments are made in innovative healthcare companies. | – | phase4-partners.com | London, United Kingdom | |
Early stage VC firm investing in the US and Korea | – | oxbio.com | Boston, United States | |
Buyouts are targeted through private equity investments by the firm. | 2001 | bisoncapital.com | Santa Monica, United States |
Investor details for Catalyst Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Catalyst Biosciences
7 people are tracked at Catalyst Biosciences (5 in leadership, 2 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Han Ying | CEO | Leadership |
Tom Knudsen | VP, Translational Research | Leadership |
Clinton Musil | Chief Financial Officer | Leadership |
Howard Levy | Chief Medical Officer | Leadership |
Janet H. | Senior Director Project Management | Leadership |
Norah Conway | Management Team | Team |
Charles Democko | SVP, Regulatory Affairs | Team |
Complete people profiles for Catalyst Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Catalyst Biosciences
Catalyst Biosciences is a publicly listed company on the NASDAQ with ticker symbol CBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Apr 2006
- Listed onNASDAQ: CBIO
- Listed entityCrescent Biopharma, Inc.
- Exchange sectorHealth technology
- ISINKYG2545C1042
- Share price$14.91 (+5.59% on the day) · 2026-10-09
- Market capitalisation$553.8M
- EPS (diluted, trailing year)$-7.65
- Volume (last session)347,149
Financials of Catalyst Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $10.8M | -$153.9M | -$152.6M |
| 2024 | – | -$17.9M | -$17.2M |
| 2023 | $10,000 | -$36.9M | -$39.1M |
| 2022 | $75,000 | -$46.7M | -$46.4M |
| 2021 | $1.2M | -$63.4M | -$62.4M |
Detailed financial statements for Catalyst Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Catalyst Biosciences
4 dated milestones of Catalyst Biosciences across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Catalyst Biosciences is founded.
- Funding First funding round of $31.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.9M.
Web traffic of Catalyst Biosciences
The website of Catalyst Biosciences (catalystbiosciences.com) receives about 2.3K visits a month and ranks #7,441,172 among all websites worldwide, #7,019 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▲ 7.9% vs previous month
- Global rank#7,441,172
among all websites
- Category rank#7,019
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit39 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Catalyst Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| merck.com | 100% | 656.8K | #78,842 | View details | |
| cymabay.com | 97% | – | – | View details |
Latest news on Catalyst Biosciences
Complete news archive for Catalyst Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Catalyst Biosciences
10 companies that operate in the same segment as Catalyst Biosciences (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Catalyst Biosciences
Catalyst Biosciences was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Catalyst Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Han Ying is the current CEO of Catalyst Biosciences.
Catalyst Biosciences is a funded company, having raised a total of $164.82M across 14 funding rounds to date. The company's 1st funding round was a Series B of $33M, raised on Aug 2000.
Catalyst Biosciences has 26 employees.
Annual revenue of Catalyst Biosciences is $10.84M as on Dec 31, 2025.
Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover and develop essential medicines across range of diseases. scientific research is currently devoted to the creation and clinical development of improved, next-generation, pro-coagulant proteases and novel proteases that cleave targets in the complement cascade, Exceptional Science and Essential Medicines. Pipeline includes FVIIa: CB 813dPF-0520602 for surgical bleeding, FIX: CB 2679dIsu 304 for hemophilia B, FXa for universal pro-coagulant, Anti-C3: CB 2782 for renal delayed graft function (DGF) and Anti-C3: Ophthalmic for dry age-related macular degeneration (AMD).
Yes, Catalyst Biosciences is publicly traded on NASDAQ under the ticker symbol CBIO.
Catalyst Biosciences has 23 investors. Key investors include Pfizer, Novartis, Icon Ventures, Nomura, and Burrill and Company.
Catalyst Biosciences operates through Catalyst Biosciences, Inc..